IPO Biophytis

EnterNext welcomes Biophytis on Alternext in Paris

Stanislas Veillet, CEO and co-founder of Biophytis, rings the opening bell.

Biophytis specializes in the development of nutraceuticals and drugs with active phytonutriments for the treatment of metabolic and aging diseases.
The company has a portfolio of 2 nutraceutical assets in clinical phase (Quinolia for the treatment of obesity and Bixilia for the protection of the skin from UV rays) and drug candidates in preclinical phase (treatment of sarcopenic obesity and age-related macular degeneration).